Advanced Instruments Introduces GloCyte<sup>®</sup> Automated Cell Counter for CSF
Provides accurate low cell counts like never before
9 Aug 2016
Advanced Instruments Inc. launched their GloCyte Automated Cell Counter System at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, PA July 31st –August 4th.
Advanced Instruments featured their new technology for the clinical laboratory in their booth (#449) and presented a poster (Number A-290) titled GloCyte: A New Automated Technology for Cerebrospinal Fluid (CSF) Cell Counts by Linda Sandhaus, M.D. of the University Hospitals Case Medical Center at the meeting on August 2nd.
Advanced Instruments recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls.
The patented GloCyte System is intended to provide a quantitative determination of red blood cells (RBCs) and total nucleated cells (TNCs) in cerebrospinal fluid (CSF) collected from adult and pediatric patients. CSF is collected when physicians rely on cell counts to assist the diagnosis of infections, inflammatory processes, hemorrhage, leukemia, and malignancies that may involve the central nervous system (CNS). Currently, low cell counts can present a challenge to standard methods.
“To date, there has not been a way to provide dependable, low cell counts,” said John Coughlin, President and CEO of Advanced Instruments. “We use a novel combination of fluorescence, microscopy with digital image analysis principles, highly specific reagents, and an intelligent counting algorithm to provide accurate and precise cell counts. We are very excited as this marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results.”
Additional benefits of the GloCyte System are that the test requires only 30 microliters of sample per test and provides timely results. It uses disposable test cartridges, ensuring no sample carryover and easy disposal, and it includes built-in quality control of Levey-Jennings charts and an audit table. The company expects to begin GloCyte shipments in September of this year.